Standard BioTools Inc. (LAB)

NASDAQ: LAB · IEX Real-Time Price · USD
-0.17 (-5.86%)
At close: Oct 2, 2023, 4:00 PM
-0.08 (-2.93%)
After-hours: Oct 2, 2023, 7:30 PM EDT

Company Description

Standard BioTools Inc., together with its subsidiaries, creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide.

It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology.

The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays.

Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions.

It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations.

It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022.

Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Standard BioTools Inc.
Standard BioTools logo
Country United States
Founded 1999
IPO Date Feb 10, 2011
Industry Diagnostics & Research
Sector Healthcare
Employees 523
CEO Dr. Michael Egholm Ph.D.

Contact Details

2 Tower Place, Suite 2000
South San Francisco, California 94080
United States
Phone (650) 266-6000

Stock Details

Ticker Symbol LAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001162194
CUSIP Number 34385P108
ISIN Number US34385P1084
Employer ID 77-0513190
SIC Code 3826

Key Executives

Name Position
Vikram Jog Chief Financial Officer
Dr. Michael Egholm Ph.D. President, Chief Executive Officer and Director
Dr. Stephen R. Quake D.phil., Ph.D. Co-Founder and Chairman of Advisory Board
Hanjoon Kim Chief Operating Officer
Andrew Quong Ph.D. Chief Science Officer
Peter DeNardo Investor Relations
Rafael Aguirre-Sacasa Acting General Counsel
Mark Spearman Senior Director of Corporate Communications
Angela Peters Chief Human Resources Officer
Dr. David A. King Ph.D. Senior Vice President of Global Research & Development

Latest SEC Filings

Date Type Title
Aug 23, 2023 144 Filing
Aug 17, 2023 144 Filing
Aug 11, 2023 144 Filing
Aug 8, 2023 10-Q Quarterly Report
Aug 8, 2023 8-K Current Report
Jul 28, 2023 8-K Current Report
Jul 7, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jul 3, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jun 20, 2023 S-8 Securities to be offered to employees in employee benefit plans
Jun 16, 2023 8-K Current Report